Clinical Trial Detail

NCT ID NCT02983604
Title GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer
Recruitment Terminated
Gender female
Phase Phase Ib/II
Variant Requirements yes
Sponsors Gilead Sciences
Indications

Her2-receptor negative breast cancer

Therapies

Exemestane

GS-5829 + Fulvestrant

GS-5829 + Exemestane

Fulvestrant

Age Groups: senior adult

Additional content available in CKB BOOST